Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
2.
Neoplasma ; 53(2): 136-43, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16575469

RESUMO

The results of clinical and laboratory observations of 119 MDS patients divided acc. to FAB, and - after excluding RAEB-t and CMML groups -- of 95 patients divided accordingly to WHO classification are presented. The diagnosis of MDS was based on medical interview, physical examination, blood biochemistry, peripheral blood (PB) and bone marrow (BM) cytomorphology and cytochemistry, trephine biopsy and cytogenetic examination. All hematologic examinations were done according to routine methods. Cytogenetic analyses were carried out on BM cells from 24-48 h cultures in standard conditions. At least 15-20 GTG-banded metaphases were analyzed in every patient. The survival time (ST) of patients differed significantly between the FAB or WHO groups, with p=0.0004 for FAB and p=0.02 for WHO. The progression to AML was more common in less favorable groups, with p=0.0001 for FAB and p=0.00016 for WHO. The distribution of IPSS prognostic index among the groups showed statistically significant difference (p=0.0004 for FAB, and p=0.0001 for WHO), whereas the distribution of karyotypic abnormalities did not. However, in univariate analysis statistically significant influence on ST showed, beside the both classification systems: cytogenetics, the presence of blasts in PB, age and IPSS index. In multivariate analysis the sole independent prognostic factors were: PB blasts and cytogenetics. The authors conclude that the WHO classification offers a good prognostic tool for MDS patients. However, the karyotype and the presence of blasts in PB should always be taken into account.


Assuntos
Síndromes Mielodisplásicas/classificação , Síndromes Mielodisplásicas/diagnóstico , Organização Mundial da Saúde , Adulto , Idoso , Feminino , Humanos , Hibridização in Situ Fluorescente , Cariotipagem , Masculino , Pessoa de Meia-Idade , Síndromes Mielodisplásicas/genética , Prognóstico , Análise de Sobrevida
3.
Pol Arch Med Wewn ; 103(1-2): 15-22, 2000.
Artigo em Polonês | MEDLINE | ID: mdl-11236254

RESUMO

Chromosomal changes during therapy with IFN-alpha were analysed in 21 patients suffering of chronic granulocytic leukemia. Complete or major cytogenetic response (CgR) was obtained in 4 patients, minor in 5 minimal in 7, and no response in 5 patients. Patients showing a low Sokal index more often disclosed CgR. In 6 persons additional chromosomal aberrations were present at diagnosis or during the disease course. They disappeared on IFN-alpha therapy. This fact may be in favour of the influence of IFN-alpha not only on disappearance of Ph chromosome, but also of secondary aberrations, some of them indicating the possibility of an acceleration of the disease. No relation of the CgR, as well as Sokal index value to the survival time in presented small cohort could be observed, which may depend on short observation time. CgR did not depend on a type of fusion of BCR/ABL gene. However, survival time was longer in patients with b3a2 fusion.


Assuntos
Aberrações Cromossômicas , Interferon-alfa/uso terapêutico , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Cromossomo Filadélfia , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Indução de Remissão
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA